Prevalence of Extended Spectrum Betalactamase (ESBL) and Metallobetalactamase (MBL) ProducingPseudomonas aeruginosaandAcinetobacter baumanniiIsolated from Various Clinical Samples

Kaur, Amandeep; Singh, Satnam

doi:10.1155/2018/6845985

Cited by 48 publications

(47 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive rate was 51.6%, higher than the rate of 21.8% and 37.5% reported in other studies. 13 In the present study, there were five IMP-positive strains (15.5%) and four VIM-positive strains (12.5%), similar to the results reported previously. 14,15 However, 27 strains were SIM-positive (84.4%), which was the most prevalent MBL gene in our study.…”

Section: Discussionsupporting

confidence: 92%

High Expression of Metallo-β-Lactamase Contributed to the Resistance to Carbapenem in Clinical Isolates of Pseudomonas aeruginosa from Baotou, China

Xu¹,

Niu²,

TongPing³

et al. 2020

IDR

View full text Add to dashboard Cite

Background: Bacterial resistance to antibiotics has become a major public health concern. This study aimed to determine the resistance mechanisms to carbapenem in clinical isolates of Pseudomonas aeruginosa. Methods: A total of 62 clinical isolates of carbapenem-resistant P. aeruginosa (CRPA) were collected from 2015 to 2017. Imipenem (IPM)-EDTA disk synergy test was used to screen strains that produced metallo-β-lactamase. In addition, the genes for outer membrane protein OprD2, metallo-β-lactamase and mexR gene were amplified and sequenced. Expression of mexA was detected by real-time PCR. Results: Disk synergy test showed that 51.6% (32/62) of the strains were positive for metallo-βlactamase. PCR showed that 84.4% of the strains were SIM-positive (27/32), 15.6% of the strains were IMP-positive (5/32), and 12.5% of the strains were VIM-positive (4/32). SPM-positive and GIM-positive strains were not detected. In addition, 5 of the 62 strains had small deletions and/or point mutations in OprD2. Three strains had a high expression of mexA, while eight strains were positive for the regulatory gene mexR with no mutations detected by DNA sequencing. Conclusion: Expression of metallo-β-lactamase is the main resistance mechanism of P. aeruginosa to carbapenem. Mutations in OprD2 and/or the overexpression of efflux pump MexAB-OprM may contribute to P. aeruginosa resistance to carbapenem.

show abstract

Section: Discussionsupporting

confidence: 92%

High Expression of Metallo-β-Lactamase Contributed to the Resistance to Carbapenem in Clinical Isolates of Pseudomonas aeruginosa from Baotou, China

Xu¹,

Niu²,

TongPing³

et al. 2020

IDR

View full text Add to dashboard Cite

show abstract

“…20 There is a high prevalence of beta lactamases an metallobetalactamases production from the isolates of P. aeruginosa and A. baumanni in different samples. 21 Kaur et al 2017 reported that the mortality rate of the blood stream infection due to colistin resistance in Klebsiella pneumoniae is 69.3% in a group of Indian patients. 22 A prospective study conducted in the intensive care units of Delhi reported that the neonatal sepsis caused by Acinetobacter baumanii and Klebsiella pneumonia and the bacterial strains were multi drug resistant.…”

Section: Emerging Trends In Antimicrobial Resistancementioning

confidence: 99%

Antibiotic Resistance: What is there in Past, Present and Future?

Priyadharsini¹

2019

JYP

View full text Add to dashboard Cite

The burden of the resistance to the antibiotics increases day by day and there is a high chance that even minor infections can kill patients in future. There is a high resistance to third generation cephalosporins and fluoroquinolones among Acinietobacter baumanni, Escherchia coli, Klebsiella pneumonia and Pseudomonas aeruginosa. The carbapenam resistance is also increasing among these bacteria. The colistin is the drug used in the treatment of carbapenam resistance and the colistin resistance also has increased. CDSCO has restricted the use of higher antibiotics carbapenams class III and IV for resistant infections. The factors influencing antibiotic resistance are many and WHO has recommended strategies to decrease the mortality and morbidity of antibiotic resistance.

show abstract

“…On the other hand, third generation cephalosporins (3GCs) have been prescribed to treat quinolone‐resistant bacteria despite low cephalosporin‐susceptibility rate . In India, 25%–89% quinolone resistance and 36%–96% 3GCs resistance has been reported among Enterobacteriaceae in different parts of the country . Thus, quinolone and cephalosporin drugs might not be a good treatment option for pathogenic ESBL‐QR Enterobacteriaceae .…”

Section: Introductionmentioning

confidence: 99%

Sub‐acute toxicological and behavioural effects of two candidate therapeutics, cinnamaldehyde and eugenol, for treatment of ESBL producing‐quinolone resistant pathogenic Enterobacteriaceae

Dhara

Tripathi

2020

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Present study deals with evaluation of antibacterial activity of cinnamaldehyde and eugenol against both extended‐spectrum‐β‐lactamase (ESBL)‐producing and quinolone resistant (QR) (ESBL‐QR) pathogenic Enterobactericeae along with determination of its in vivo toxicity level in a murine model to investigate their pharmacological potential. Broth microdilution assay was used to determine minimum inhibitory concentrations (MICs) of cinnamaldehyde (CIN), eugenol (EG) and traditional antibiotics against ESBL‐QR Enterobactericeae. Sub‐acute oral toxicity study (14 days) was carried out in Swiss albino mice to evaluate any toxicological and behavioural effect viz novelty suppressed feeding (NSF), novel object recognition (NOR), tail suspension test (TST) and social interaction test of cinnamaldehyde and eugenol. Cinnamaldehyde and eugenol demonstrated mode‐MIC of 7.28 and 7.34 μg/mL among maximum numbers of Escherichia coli (32.1%) and 0.91 and 3.67 μg/mL among maximum numbers of Klebsiella pneumoniae (24.2%) isolates, respectively. For haematological and toxicological analyses, after 14 days of oral administration of cinnamaldehyde (0.91–10 mg/kg) and eugenol (7.34–70 mg/kg), blood was collected from the murine model, while histological examinations were performed on liver and kidney. There was no alteration in food and water intake among treated animals. Toxicological and behavioural studies displayed good safety profiles of cinnamaldehyde and eugenol. The results indicated potential antibacterial efficacy of cinnamaldehyde and eugenol against pathogenic ESBL‐QR Enterobacteriaceae, without any significant toxicological and behavioural effects.

show abstract

Prevalence of Extended Spectrum Betalactamase (ESBL) and Metallobetalactamase (MBL) ProducingPseudomonas aeruginosaandAcinetobacter baumanniiIsolated from Various Clinical Samples

Cited by 48 publications

References 15 publications

<p>High Expression of Metallo-β-Lactamase Contributed to the Resistance to Carbapenem in Clinical Isolates of <em>Pseudomonas aeruginosa</em> from Baotou, China</p>

<p>High Expression of Metallo-β-Lactamase Contributed to the Resistance to Carbapenem in Clinical Isolates of <em>Pseudomonas aeruginosa</em> from Baotou, China</p>

Antibiotic Resistance: What is there in Past, Present and Future?

Sub‐acute toxicological and behavioural effects of two candidate therapeutics, cinnamaldehyde and eugenol, for treatment of ESBL producing‐quinolone resistant pathogenic Enterobacteriaceae

Contact Info

Product

Resources

About